204 related articles for article (PubMed ID: 20205998)
1. [Therapeutic drug monitoring of oxcarbazepine].
Bouquié R; Dailly E; Bentué-Ferrer D;
Therapie; 2010; 65(1):61-5. PubMed ID: 20205998
[TBL] [Abstract][Full Text] [Related]
2. [Not Available].
Bouquié R; Dailly E; Bentué-Ferrer D;
Therapie; 2010; 65(1):61-5. PubMed ID: 27392926
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of oxcarbazepine.
May TW; Korn-Merker E; Rambeck B
Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD).
Miles MV; Tang PH; Ryan MA; Grim SA; Fakhoury TA; Strawsburg RH; DeGrauw TJ; Baumann RJ
Ther Drug Monit; 2004 Jun; 26(3):300-4. PubMed ID: 15167632
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK
Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326
[TBL] [Abstract][Full Text] [Related]
6. Does oxcarbazepine warrant therapeutic drug monitoring? A critical review.
Bring P; Ensom MH
Clin Pharmacokinet; 2008; 47(12):767-78. PubMed ID: 19026033
[TBL] [Abstract][Full Text] [Related]
7. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy.
Pisani F; Fazio A; Oteri G; Artesi C; Xiao B; Perucca E; Di Perri R
Acta Neurol Scand; 1994 Aug; 90(2):130-2. PubMed ID: 7801739
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy.
Kim DW; Gu N; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Kim HS; Oh J; Lee SK
Epilepsia; 2012 Jan; 53(1):e9-12. PubMed ID: 22091603
[TBL] [Abstract][Full Text] [Related]
9. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
Lu Y; Fang Y; Wu X; Ma C; Wang Y; Xu L
Eur J Clin Pharmacol; 2017 Mar; 73(3):307-315. PubMed ID: 27900402
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic drug monitoring of zonisamide].
Verdier MC; Bentué-Ferrer D; Tribut O;
Therapie; 2010; 65(1):29-34. PubMed ID: 20205992
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
Johannessen SI; Tomson T
Clin Pharmacokinet; 2006; 45(11):1061-75. PubMed ID: 17048972
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.
Yu Y; Zhang Q; Xu W; Lv C; Hao G
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):345-51. PubMed ID: 25700977
[TBL] [Abstract][Full Text] [Related]
13. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy.
Sattler A; Schaefer M; May TW
Seizure; 2015 Sep; 31():149-54. PubMed ID: 26362393
[TBL] [Abstract][Full Text] [Related]
14. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium.
Mazzucchelli I; Onat FY; Ozkara C; Atakli D; Specchio LM; Neve AL; Gatti G; Perucca E
Epilepsia; 2006 Mar; 47(3):504-9. PubMed ID: 16529613
[TBL] [Abstract][Full Text] [Related]
15. Saliva and Plasma Monohydroxycarbamazepine Concentrations in Pediatric Patients With Epilepsy.
Li RR; Sheng XY; Ma LY; Yao HX; Cai LX; Chen CY; Zhu SN; Zhou Y; Wu Y; Cui YM
Ther Drug Monit; 2016 Jun; 38(3):365-70. PubMed ID: 26818624
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic drug monitoring of vigabatrin].
Bentué-Ferrer D; Tribut O; Verdier MC;
Therapie; 2010; 65(1):23-7. PubMed ID: 20205991
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetic variability of oxcarbazepine in epileptic patients].
Viola MS; Bercellini MA; Saidón P; Rubio MC
Medicina (B Aires); 2000; 60(6):914-8. PubMed ID: 11436701
[TBL] [Abstract][Full Text] [Related]
18. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance.
Baruzzi A; Albani F; Riva R
Epilepsia; 1994; 35 Suppl 3():S14-9. PubMed ID: 8156974
[TBL] [Abstract][Full Text] [Related]
19. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders.
Grant SM; Faulds D
Drugs; 1992 Jun; 43(6):873-88. PubMed ID: 1379159
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities.
Sugiyama I; Bouillon T; Yamaguchi M; Suzuki H; Hirota T; Fink M
Drug Metab Pharmacokinet; 2015 Apr; 30(2):160-7. PubMed ID: 25989891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]